Drug Profile
TAK 065
Alternative Names: TAK-065Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 11 May 2011 Discontinued - Phase-I for Alzheimer's disease in Japan (PO)
- 11 May 2011 Discontinued - Phase-I for Parkinson's disease in Japan (PO)